Articles that tag OSTX but are mainly about other companies.
FDA elevated Type D Biomarker Meeting to Type B pre-BLA Meeting for OST-HER2; holds Orphan Drug, Fast Track, and Rare Pediatric Disease Designations; eligible for Priority Review Voucher worth ~$205 million if approved; targeting Accelerated Approval in 2H 2026.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
